ArticleRenal failure2025
Lumican as a potential biomarker for diabetic nephropathy.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Overexpression of LINC00472 alleviates diabetic kidney disease progression via the miR-21-5p/STAT3 axis.Renal failure · 2026Article
- Keratan Sulfate: An Electroconductive Glycosaminoglycan at the Interface of Sensory Perception and Neural Signaling.Journal of neuroscience research · 2026Review
- Systemic immune indicators: Early predictors of renal damage in children with newly diagnosed type 1 diabetes mellitus.World journal of diabetes · 2025Article
- Cdk5 mediates impaired autophagy by regulating NGF/Sirt1 axis to cause diabetic islet β cell damage.Frontiers in cell and developmental biology · 2025Article
- Integrated bioinformatics and machine learning reveal pan-apoptosis and immune infiltration signatures in diabetic nephropathy.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveWe employed bioinformatics to identify potential biomarkers for diabetic nephropathy (DN) and investigate the role of the key gene lumican in its molecular processes.
methodsWe analyzed the GSE96804 and GSE30528 DN datasets from the Gene Expression Omnibus (GEO). GO and GSEA-KEGG enrichment analyses were used to identify key biological functions and related pathways. Cytoscape software was used to screen differentially expressed genes (DEGs) to obtain hub genes. The Nephroseq database was used to analyze the effect of hub genes on renal function, and the importance of lumican, a gene potentially related to DN progression, was further examined in clinical samples. GO and KEGG analyses were performed on lumican and its interacting proteins to elucidate their main biological functions and related pathways.
resultsWe identified 1139 DEGs. GO enrichment analysis revealed that the DEGs were mainly involved in responses to hexose, cell-cell junctions. GSEA-KEGG enrichment analysis indicated that the DEGs were related to amino acid metabolism, adipokine signaling. Nephroseq database analysis revealed that hub genes were upregulated in the kidney tissues of patients with DN and that their expression was negatively correlated with estimated glomerular filtration rate (eGFR). Lumican was among the top hub genes, and its expression was increased in renal tissues of DN patients as confirmed by immunohistochemistry and immunofluorescence. GO and KEGG enrichment analyses revealed that lumican and its interacting proteins were associated with extracellular matrix organization.
conclusionLumican is a potential biomarker for predicting DN and is closely related to the extracellular matrix. These findings provide novel insights into the clinical diagnosis and treatment of DN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.